Cargando…

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension

BACKGROUND: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose excipients (epoprostenol AS). METHODS: The stability of the reconstituted solutions after storage at 5°C and 25°C, diluted solutions (300...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Olivier, Bandilla, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459691/
https://www.ncbi.nlm.nih.gov/pubmed/23049244
http://dx.doi.org/10.2147/DDDT.S31628
_version_ 1782244839713144832
author Lambert, Olivier
Bandilla, Dirk
author_facet Lambert, Olivier
Bandilla, Dirk
author_sort Lambert, Olivier
collection PubMed
description BACKGROUND: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose excipients (epoprostenol AS). METHODS: The stability of the reconstituted solutions after storage at 5°C and 25°C, diluted solutions (3000–60,000 ng/mL) at controlled room temperature, and diluted solutions (3000–60,000 ng/mL) stored at 5°C and then at room temperature were evaluated. Solutions were prepared using sterile water for injection or sterile saline (sodium chloride 0.9%) for injection. Shelf-life was assessed by determining potency over time relative to initial potency. In this context, potency is synonymous with content. The antimicrobial activity of reconstituted (100,000 ng/mL for 0.5 mg vial, 300,000 ng/mL for 1.5 mg vial) and diluted (3000 ng/mL) epoprostenol AS was measured using an antimicrobial effectiveness test after inoculation with six species of bacteria, yeast, and mold. RESULTS: Reconstituted epoprostenol AS was stable for up to one day’s storage at 25°C or 7 days’ storage at 5°C. Epoprostenol AS was stable for up to 72 hours when diluted, depending on temperature and concentration. The maximum shelf-life of the diluted solution if the reconstituted solution had been stored for up to one day at room temperature or up to 7 days at 5°C, was between 24 and 72 hours, depending on concentration. Following storage of diluted solutions at 5°C for up to 8 days, maximum shelf-life was between one and 2 days, depending on temperature and concentration. Potency was not dependent on diluents. Preservative testing confirmed no microbial growth for any of six organisms tested for at least 14 days at 5°C or 25°C for the reconstituted solution and for at least 16 days at 5°C followed by one day at 25°C for the diluted solutions. CONCLUSION: Epoprostenol AS has favorable thermal stability and does not support the growth of any micro-organism tested for up to 17 days. This extended stability under ambient conditions has the potential to improve convenience further for patients.
format Online
Article
Text
id pubmed-3459691
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34596912012-10-03 Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension Lambert, Olivier Bandilla, Dirk Drug Des Devel Ther Original Research BACKGROUND: The aim of this study was to evaluate the stability and microbiological properties of a formulation of epoprostenol sodium with L-arginine and sucrose excipients (epoprostenol AS). METHODS: The stability of the reconstituted solutions after storage at 5°C and 25°C, diluted solutions (3000–60,000 ng/mL) at controlled room temperature, and diluted solutions (3000–60,000 ng/mL) stored at 5°C and then at room temperature were evaluated. Solutions were prepared using sterile water for injection or sterile saline (sodium chloride 0.9%) for injection. Shelf-life was assessed by determining potency over time relative to initial potency. In this context, potency is synonymous with content. The antimicrobial activity of reconstituted (100,000 ng/mL for 0.5 mg vial, 300,000 ng/mL for 1.5 mg vial) and diluted (3000 ng/mL) epoprostenol AS was measured using an antimicrobial effectiveness test after inoculation with six species of bacteria, yeast, and mold. RESULTS: Reconstituted epoprostenol AS was stable for up to one day’s storage at 25°C or 7 days’ storage at 5°C. Epoprostenol AS was stable for up to 72 hours when diluted, depending on temperature and concentration. The maximum shelf-life of the diluted solution if the reconstituted solution had been stored for up to one day at room temperature or up to 7 days at 5°C, was between 24 and 72 hours, depending on concentration. Following storage of diluted solutions at 5°C for up to 8 days, maximum shelf-life was between one and 2 days, depending on temperature and concentration. Potency was not dependent on diluents. Preservative testing confirmed no microbial growth for any of six organisms tested for at least 14 days at 5°C or 25°C for the reconstituted solution and for at least 16 days at 5°C followed by one day at 25°C for the diluted solutions. CONCLUSION: Epoprostenol AS has favorable thermal stability and does not support the growth of any micro-organism tested for up to 17 days. This extended stability under ambient conditions has the potential to improve convenience further for patients. Dove Medical Press 2012-09-17 /pmc/articles/PMC3459691/ /pubmed/23049244 http://dx.doi.org/10.2147/DDDT.S31628 Text en © 2012 Lambert and Bandilla, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Lambert, Olivier
Bandilla, Dirk
Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
title Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
title_full Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
title_fullStr Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
title_full_unstemmed Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
title_short Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
title_sort stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459691/
https://www.ncbi.nlm.nih.gov/pubmed/23049244
http://dx.doi.org/10.2147/DDDT.S31628
work_keys_str_mv AT lambertolivier stabilityandpreservationofanewformulationofepoprostenolsodiumfortreatmentofpulmonaryarterialhypertension
AT bandilladirk stabilityandpreservationofanewformulationofepoprostenolsodiumfortreatmentofpulmonaryarterialhypertension